| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Rabeprazole sodium (LY-307640 sodium) is a novel, potent and 2nd-generation proton pump inhibitor (PPI) that is used as an antiulcer drug. It irreversibly inactivates gastric H+/K+-ATPase and induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux. It is a partially reversible gastric proton pump inhibitor and also an inhibitor of ATP4.
| ln Vitro |
After 0.2 mM treatment for 16 hours, rabeprazole eliminated the viability of human cells [2]. In MKN-28 cells, rabeprazole totally suppressed ERK1/2 phosphorylation. MKN-28 cell line ERK 1/2 phosphorylation was significantly suppressed when the cell line was cultured in toxin media (pH 5.4) for two hours and then attenuated with rabeprazole (0.2 mM) for two hours [2].
|
|---|---|
| ln Vivo |
In female mice, rabeprazole sodium (10 mg/kg; lateral every 48 hours for 18 weeks) significantly reduces serum calcium levels, causes a decrease in bone mineral density (BMD), and results in secondary hyperparathyroidism [3].
|
| Cell Assay |
Cell Viability Assay[2]
Cell Types: Three gastric cancer cell lines KATO III, MKN-28 and MKN-45 Tested Concentrations: 0.2 mM Incubation Duration: 16 hrs (hours) Experimental Results: Treatment resulted in diminished viability of all tested cancer cell lines, comparable to KATO III Compared with MKN-28 cells, the cell viability was Dramatically diminished compared with MKN-45 cells. Western Blot Analysis[2] Cell Types: Three gastric cancer cell lines (KATO III, MKN-28 and MKN-45)[2] Tested Concentrations: 0.2 mM Incubation Duration: 2 hrs (hours) pretreatment Experimental Results: Result in strong inhibition of ERK 1/2 Phosphorylated in MKN-28 cells, but no similar effect was observed in KATO III and MKN-45 cells. |
| Animal Protocol |
Animal/Disease Models: Female Swiss albino mice (body weight 18-26 g) [3]
Doses: 10 mg/kg Route of Administration: Oral; every 48 hrs (hrs (hours)) for 18 weeks Experimental Results: Serum calcium levels compared with vehicle-treated group Dramatically lower (5.5±2.07 vs. 9.68±2.77). |
| References |
|
| Additional Infomation |
Rabeprazole sodium is an organic sodium salt. It contains a rabeprazole(1-).
Rabeprazole Sodium is the sodium salt of the prodrug rabeprazole, a substituted benzimidazole proton pump inhibitor, with potential anti-ulcer activity. After protonation, accumulation, and transformation to the active sulfenamide within the acidic environment of gastric parietal cells, rabeprazole selectively and irreversibly binds to and inhibits the H+, K+ATPase (hydrogen-potassium adenosine triphosphatase) enzyme system located on the parietal cell secretory surface, inhibiting gastric acid secretion. A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. See also: Rabeprazole (has active moiety). Drug Indication Treatment of duodenal ulcer, Treatment of gastric ulcer, Treatment of gastro-oesophageal reflux disease, Treatment of Helicobacter pylori in patients with peptic ulcer disease, Treatment of Zollinger-Ellison syndrome |
| Molecular Formula |
C18H20N3NAO3S
|
|---|---|
| Molecular Weight |
381.4245
|
| Exact Mass |
381.112
|
| CAS # |
117976-90-6
|
| Related CAS # |
Rabeprazole;117976-89-3;Rabeprazole-d4 sodium;Rabeprazole-d4;934295-48-4;Rabeprazole Sulfide;117977-21-6;Rabeprazole-d3 sodium;1216494-11-9
|
| PubChem CID |
14720269
|
| Appearance |
White to off-white solid powder
|
| Density |
0.45~0.55 g/ml
|
| Boiling Point |
603.9ºC at 760 mmHg
|
| Melting Point |
140-141ºC dec.
|
| Flash Point |
319.1ºC
|
| LogP |
3.484
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
26
|
| Complexity |
446
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
KRCQSTCYZUOBHN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H20N3O3S.Na/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18;/h3-4,6-9H,5,10-12H2,1-2H3;/q-1;+1
|
| Chemical Name |
sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]benzimidazol-1-ide
|
| Synonyms |
LY307640 sodium; LY-307640 sodium; LY 307640 sodium; Rabeprazole Sodium; Pariet; Aciphex; Rabeprazole sodium salt; Rebeprazole sodium;3810, E; Aciphex; dexrabeprazole; E 3810; E3810; LY 307640; LY-307640; LY307640;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~262.18 mM)
DMSO : ≥ 48 mg/mL (~125.85 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.45 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.45 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.45 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6218 mL | 13.1089 mL | 26.2178 mL | |
| 5 mM | 0.5244 mL | 2.6218 mL | 5.2436 mL | |
| 10 mM | 0.2622 mL | 1.3109 mL | 2.6218 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Efficacy and Safety After Multiple Doses of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules in Helicobacter Pylori Infected-positive Participants
CTID: NCT06076694
Phase: Phase 2 Status: Completed
Date: 2023-12-12
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA